Photon vs Proton Therapy To Treat Patients With Lung Cancer

PHASE III RANDOMIZED TRIAL COMPARING OVERALL SURVIVAL AFTER PHOTON VERSUS PROTON CHEMORADIOTHERAPY FOR INOPERABLE STAGE II-IIIB NSCLC

  • Clinical Trial Information

    Trial Contact: Manchola-Orozco, Carolina; Frankos, Marie

    Trial Phone: 321.841.7293 ; 321.841.7303

  • IRB No: RTOG 1308

    Protocol Abbrev: RTOG 1308

    Principal Investigator: Justin Mathew Rineer, MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: RTOG 1308

    Treatment: Photon, Proton, Chemotherapy

    Therapies Involved: Chemotherapy

    ClinicalTrials.gov ID: NCT01993810

  • Objective

    This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-III non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as photon or proton beam radiation therapy, may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether proton chemoradiotherapy is more effective than photon chemoradiotherapy in treating non-small cell lung cancer.

  • Key Eligibility

    •   Histologically or cytologically proven diagnosis of non-small cell lung cancer
    •   Clinical American Joint Committee on Cancer (AJCC) (AJCC, 7th ed.) II, IIIA or IIIB (with non-operable disease; non-operable disease will be determined by a multi-disciplinary treatment team within 60 days prior to registration; note: for patients who are clearly nonresectable, the case can be determined by the treating radiation oncologist and/or a medical oncologist or pulmonologist
    •   Patients who present with N2 or N3 disease and an undetectable NSCLC primary tumor are eligible
    •   Patients